From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy
Status:
Completed
Trial end date:
2020-06-29
Target enrollment:
Participant gender:
Summary
There is a lack of evidence on the impact of switching from a combined preserved
anti-glaucoma regimen to a preservative-free (PF) one, while employing sufficiently robust
OSD metrics. The investigators have therefore carried out a single center, prospective,
crossover investigation to compare the 6-month effect of switching well controlled open-angle
glaucoma patients with at least moderate glaucoma therapy-related ocular surface disease from
preserved to triple preservative-free therapy with and without cyclosporine 0.1% dosed in the
evening.